Titre : Famille-26 de cytochromes P450

Famille-26 de cytochromes P450 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Controlled Substances
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Famille-26 de cytochromes P450 : Questions médicales les plus fréquentes", "headline": "Famille-26 de cytochromes P450 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Famille-26 de cytochromes P450 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-04", "dateModified": "2025-03-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Famille-26 de cytochromes P450" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cytochrome P-450 enzyme system", "url": "https://questionsmedicales.fr/mesh/D003577", "about": { "@type": "MedicalCondition", "name": "Cytochrome P-450 enzyme system", "code": { "@type": "MedicalCode", "code": "D003577", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.422.220.453" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Retinoic acid 4-hydroxylase", "alternateName": "Retinoic Acid 4-Hydroxylase", "url": "https://questionsmedicales.fr/mesh/D000072516", "about": { "@type": "MedicalCondition", "name": "Retinoic acid 4-hydroxylase", "code": { "@type": "MedicalCode", "code": "D000072516", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.422.220.453.498.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Famille-26 de cytochromes P450", "alternateName": "Cytochrome P450 Family 26", "code": { "@type": "MedicalCode", "code": "D000072500", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "David R Nelson", "url": "https://questionsmedicales.fr/author/David%20R%20Nelson", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA." } }, { "@type": "Person", "name": "F Peter Guengerich", "url": "https://questionsmedicales.fr/author/F%20Peter%20Guengerich", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu." } }, { "@type": "Person", "name": "Donghak Kim", "url": "https://questionsmedicales.fr/author/Donghak%20Kim", "affiliation": { "@type": "Organization", "name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea." } }, { "@type": "Person", "name": "Emily E Scott", "url": "https://questionsmedicales.fr/author/Emily%20E%20Scott", "affiliation": { "@type": "Organization", "name": "Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu." } }, { "@type": "Person", "name": "Vitchan Kim", "url": "https://questionsmedicales.fr/author/Vitchan%20Kim", "affiliation": { "@type": "Organization", "name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.", "datePublished": "2023-01-02", "url": "https://questionsmedicales.fr/article/36595589", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5435/JAAOS-D-22-00458" } }, { "@type": "ScholarlyArticle", "name": "Psychomodulatory substances: New legislative framework for control of psychoactive substances in Czechia.", "datePublished": "2024-10-09", "url": "https://questionsmedicales.fr/article/39388916", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugpo.2024.104603" } }, { "@type": "ScholarlyArticle", "name": "Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.", "datePublished": "2023-06-09", "url": "https://questionsmedicales.fr/article/37348270", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugalcdep.2023.110819" } }, { "@type": "ScholarlyArticle", "name": "The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35947832", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5435/JAAOS-D-22-00433" } }, { "@type": "ScholarlyArticle", "name": "Diverting Data and Drugs: A Narrative Review of the Mallinckrodt Documents.", "datePublished": "2024-05-31", "url": "https://questionsmedicales.fr/article/38818605", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1017/jme.2024.60" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Hémoprotéines", "item": "https://questionsmedicales.fr/mesh/D006420" }, { "@type": "ListItem", "position": 5, "name": "Cytochromes", "item": "https://questionsmedicales.fr/mesh/D003580" }, { "@type": "ListItem", "position": 6, "name": "Cytochrome P-450 enzyme system", "item": "https://questionsmedicales.fr/mesh/D003577" }, { "@type": "ListItem", "position": 7, "name": "Famille-26 de cytochromes P450", "item": "https://questionsmedicales.fr/mesh/D000072500" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Famille-26 de cytochromes P450 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Famille-26 de cytochromes P450", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Famille-26 de cytochromes P450", "description": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?\nQuels tests sont utilisés pour évaluer l'activité des CYP26 ?\nLes symptômes cliniques aident-ils au diagnostic ?\nPeut-on utiliser l'imagerie pour le diagnostic ?\nLes antécédents médicaux sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Controlled+Substances&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Famille-26 de cytochromes P450", "description": "Quels sont les symptômes d'une anomalie des CYP26 ?\nLes anomalies des CYP26 causent-elles des douleurs ?\nY a-t-il des symptômes cutanés associés ?\nLes troubles de l'humeur sont-ils liés aux CYP26 ?\nLes anomalies des CYP26 affectent-elles la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Controlled+Substances&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Famille-26 de cytochromes P450", "description": "Comment prévenir les dysfonctionnements des CYP26 ?\nLes tests génétiques peuvent-ils prévenir des problèmes ?\nL'évitement de certains médicaments est-il conseillé ?\nLe suivi médical régulier est-il important ?\nLes habitudes de vie influencent-elles la santé des CYP26 ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Controlled+Substances&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Famille-26 de cytochromes P450", "description": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?\nLes modifications alimentaires aident-elles ?\nDes médicaments spécifiques sont-ils utilisés ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Controlled+Substances&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Famille-26 de cytochromes P450", "description": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?\nLes anomalies des CYP26 peuvent-elles causer des maladies chroniques ?\nY a-t-il un risque accru de cancer ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Controlled+Substances&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Famille-26 de cytochromes P450", "description": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?\nL'âge influence-t-il le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils importants ?\nLes maladies préexistantes augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Controlled+Substances&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer les anomalies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des CYP26 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques et des dosages de métabolites spécifiques sont utilisés." } }, { "@type": "Question", "name": "Les symptômes cliniques aident-ils au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme des troubles hormonaux peuvent indiquer une dysfonction." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer les CYP26." } }, { "@type": "Question", "name": "Les antécédents médicaux sont-ils importants ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents de traitement médicamenteux peuvent influencer le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une anomalie des CYP26 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes incluent des troubles métaboliques et des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les anomalies des CYP26 causent-elles des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner des douleurs liées à des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées peuvent survenir en raison de déséquilibres métaboliques." } }, { "@type": "Question", "name": "Les troubles de l'humeur sont-ils liés aux CYP26 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles de l'humeur peuvent être liés à des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les anomalies des CYP26 affectent-elles la fertilité ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent affecter la fertilité en perturbant les niveaux hormonaux." } }, { "@type": "Question", "name": "Comment prévenir les dysfonctionnements des CYP26 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine et un suivi médical régulier peuvent aider à prévenir." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils prévenir des problèmes ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les risques avant l'apparition des symptômes." } }, { "@type": "Question", "name": "L'évitement de certains médicaments est-il conseillé ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, éviter les médicaments connus pour interférer avec les CYP26 peut être bénéfique." } }, { "@type": "Question", "name": "Le suivi médical régulier est-il important ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier permet de détecter précocement les anomalies." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles la santé des CYP26 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de vie saines peuvent améliorer la fonction des CYP26." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies hormonales et des ajustements médicamenteux." } }, { "@type": "Question", "name": "Les modifications alimentaires aident-elles ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut soutenir le métabolisme hormonal." } }, { "@type": "Question", "name": "Des médicaments spécifiques sont-ils utilisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments ciblant les déséquilibres hormonaux peuvent être prescrits." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est encore en recherche pour traiter les anomalies des CYP26." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles métaboliques graves et des déséquilibres hormonaux." } }, { "@type": "Question", "name": "Les anomalies des CYP26 peuvent-elles causer des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent contribuer à des maladies chroniques comme le diabète." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies peuvent augmenter le risque de cancers hormonodépendants." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement altérer la qualité de vie." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux et l'exposition à certains médicaments." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque peut augmenter avec l'âge en raison de changements hormonaux." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils importants ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines environnementales peut affecter les CYP26." } }, { "@type": "Question", "name": "Les maladies préexistantes augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies peuvent prédisposer à des anomalies des CYP26." } } ] } ] }

Sources (10000 au total)

A Retrospective Cohort Study on Chronic Opioid Use After Geriatric Hip Fracture Surgery-Risk Factors, Trends, and Outcomes.

The purpose of this study is to identify the risk factors for prolonged opioid use after surgery in geriatric hip fracture patients and the effects of prolonged use on mortality and readmission rates.... An institutional registry was queried for all patients older than 65 years who underwent surgical treatment of a hip fracture between January 2016 and June 2017. Using the Controlled Substance Utiliza... Of 500 patients who underwent hip-fracture surgery during the study period, a total of 322 had complete Controlled Substance Utilization Review and Evaluation System data. 36.0% (116) were OE, and 64.... Opioid use in geriatric hip fracture patients is high both preoperatively and postoperatively. Opioid exposed patients and patients on antidepressants are more likely to continue opioids at 6 months. ... Level III....

Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: An ethnographic and drug checking study.

Fentanyl- and methamphetamine-based counterfeit prescription drugs have driven escalating overdose death rates in the US, however their presence in Mexico has not been assessed. Our ethnographic team ... To characterize the availability of counterfeit and authentic controlled substances at pharmacies in Northern Mexico available to English-speaking tourists without a prescription.... We employed an iterative, exploratory, mixed methods design. Longitudinal ethnographic data was used to characterize tourist-oriented micro-neighborhoods and guide the selection of n=40 pharmacies in ... Of n=40 pharmacies, one or more of the requested controlled substances could be obtained with no prescription (as single pills or in bottles) at 28 (70.0%) and as single pills at 19 (47.5%). Counterfe... The availability of fentanyl-, heroin-, and methamphetamine-based counterfeit medications in tourist-oriented independent pharmacies in Northern Mexico represents a public health risk, and occurs in t...

The Effect of Online Prescription Drug Monitoring on Opioid Prescription Habits After Elective Single-level Lumbar Fusion.

The United States opioid epidemic is a well-documented crisis stemming from increased prescriptions of narcotics. Online prescription drug monitoring programs (PDMPs) are a potential resource to mitig... Patients who underwent a single-level lumbar fusion between August 27, 2017, and August 31, 2020, were identified and placed categorically into one of two cohorts: an "early adoption" cohort, Septembe... No significant difference was observed in preoperative opioid prescriptions between the early and late adoption cohorts. The late adoption group independently predicted decreased postoperative opioid ... PDMP implementation was associated with decreased postoperative opioid prescription patterns but not preoperative opioid prescribing behaviors.... 4....

Real or fake? Sourcing and marketing of non-prescribed benzodiazepines amongst two samples of people who regularly use illicit drugs in Australia.

There is concern around non-prescribed benzodiazepine use, particularly with increasing detections of counterfeit products containing high-risk novel compounds. The aims of this study were to investig... Data were collected from a sample of Australians who inject drugs or use ecstasy and/or other illicit stimulants on a monthly or more frequent basis, and who reported past 6-month use of non-prescribe... Amongst participants who injected drugs, 71% reported that their last non-prescribed benzodiazepines were diverted from a known/trusted prescription, compared to 59% of participants who used ecstasy/o... Most participants obtained substances sold as classic/registered benzodiazepines, mostly via diverted prescriptions, with a substantial minority potentially unaware of counterfeits circulating. While ...

Effect of Integrating Access to a Prescription Drug Monitoring Program Within the Electronic Health Record on the Frequency of Queries by Primary Care Clinicians: A Cluster Randomized Clinical Trial.

Tools that are directly integrated with the electronic health record (EHR) workflow can reduce the hassle cost of certain guideline-concordant practices, such as querying a prescription drug monitorin... To investigate the effect of integrating access to a PDMP within the EHR on the frequency of program queries by primary care clinicians.... The PRINCE (Prescribing Interventions for Chronic Pain Using the Electronic Health Record) randomized trial used a factorial cluster design at the clinic level in 43 primary care clinics in Minnesota.... Single sign-on access to the Minnesota PDMP was integrated into the EHR, allowing clinicians to query a patient's controlled substance prescription and dispensing history as recorded in the Minnesota ... Monthly PDMP query counts for primary care clinicians, overall and by modality (EHR-based, web-based, via a clinical delegate), adjusted for clinician characteristics, including type (physician, nurse... Of the 43 participating clinics with 309 clinicians, 21 clinics with 161 clinicians (102 [63.4%] women; 114 [70.8%] physicians; tenure, 10.6 [4.4] years) received the PDMP integration intervention. Ba... This cluster randomized clinical trial found that integrating access to the PDMP in the EHR increased PDMP-querying rates, suggesting that direct access reduced hassle costs and can dramatically impro... ClinicalTrials.gov Identifier: NCT04601506....

Prescription drug monitoring programs use mandates and prescription stimulant and depressant quantities.

While the mandate to check patients' prescription history in Prescription Drug Monitoring Program (PDMP) database before prescribing/dispensing controlled drugs has been shown to be an important tool ... Using data from Automated Reports and Consolidate Ordering System (ARCOS), we employed difference-in-differences design to estimate the association between PDMP use mandates and prescription stimulant... There was no evidence that limited PDMP use mandate was associated with a reduction in the prescription stimulant and depressant quantities. However, expansive PDMP use mandate that was non-specific t... Expansive PDMP use mandate was associated with a decline in prescription amphetamine quantity. Limited PDMP use mandate did not appear to change prescription stimulant and depressant quantities....

Review and inventory of 911 Good Samaritan Law Provisions in the United States.

911 Good Samaritan Laws (GSLs) confer limited legal immunity to bystanders in possession of controlled substances who report emergency overdoses. While these laws may decrease opioid overdose mortalit... We identified all state GSLs and their legislative history, characterizing features into four categories using a novel framework: breadth of protected activities, burden placed on Good Samaritans, str... GSLs vary substantially across states and time. Protections depend on the quantity of substances involved and may extend to the person experiencing the overdose or persons reporting their own overdose... States offer Good Samaritans substantially different protections even when the statutes confer nominally comparable immunities. Accommodating this heterogeneity will enhance the validity of future stu...